Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial

By G. Wilcock, S. Lilienfeld, E. Gaens. British medical journal, 2000

610 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia (2003, neutral): “Calculations were also included for galantamine, using the results from another trial (Wilcock et al, 2000).”
Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, background): “…has a significant therapeutic effect in the management of patients with Alzheimer’s disease (Erkinjuntti et al., 2008; Erkinjuntti et al., 2002; Kaduszkiewicz et al., 2005; Kavirajan and Schneider, 2007; Loy and Schneider, 2006; Raskind et al., 2000; Tariot et al., 2000; Wilcock et al., 2000).”
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. (2020, neutral): “Memory, language skills, and reasoning capabilities were assessed using the ADAS-cog scale (Raskind et al., 2000; Tariot et al., 2000; Wilcock et al., 2000; Rockwood et al., 2010; Wilkinson and Murray, 2001; Brodaty et al., 2005).”
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline (2008, background): “Outcomes of harm Anorexia 6 (39, 40, 41, 42, 45, 46) Some limitations No important inconsistency (I(2) 0.”